Vertex Pharmaceuticals (VRTX) EBITDA (2009 - 2026)

Vertex Pharmaceuticals' EBITDA history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, EBITDA rose 80.62% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $4.7 billion (up 730.65% YoY), while the FY2025 annual figure was $4.2 billion, up 1891.88% from the prior year.
• EBITDA was $1.1 billion for Q1 2026 at Vertex Pharmaceuticals, down from $1.2 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.2 billion in Q4 2025 to a low of -$3.5 billion in Q2 2024.
• Historically, EBITDA has averaged $777.5 million across 5 years, with a median of $1.0 billion in 2022.
• The sharpest annual moves came in 2022 and 2024: EBITDA soared 3019.0% in 2022, then slumped 442.43% in 2024.
• A 5-year view of EBITDA shows it stood at $1.0 billion in 2022, then declined by 4.35% to $988.5 million in 2023, then rose by 3.79% to $1.0 billion in 2024, then grew by 17.53% to $1.2 billion in 2025, then dropped by 5.62% to $1.1 billion in 2026.
• The last three EBITDA figures came in at $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.